Needham Maintains Buy on Cytokinetics, Raises Price Target to $108
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has maintained a Buy rating on Cytokinetics (NASDAQ:CYTK) and increased the price target from $60 to $108.
December 27, 2023 | 6:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger maintains a Buy rating on Cytokinetics and raises the price target from $60 to $108, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst typically signals a strong conviction in the company's future performance and growth potential. This can lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100